Trial Profile
A Phase I Study of Pyrotinib In Combination With Docetaxel In Patients With HER2 Positive Advanced Gastric Cancer
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Pyrotinib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 10 Mar 2015 New trial record